Peer Exchange | Page 2

A unique opportunity to view lively discussions featuring peer-to-peer exchanges that provide authoritative insights, opinions, and perspectives on important issues facing today's cancer care professionals.

Browse by Series:

Activity of Immunotherapy in the Frontline Setting

New Data for Checkpoint Inhibitors in NSCLC

Bladder Cancer: Real-World Experience With Immunotherapy

PD-L1 Testing for NSCLC

FDA Approval of Atezolizumab for Advanced Bladder Cancer

Upfront Use of Immunotherapy for NCSLC

PD-L1 Expression in Bladder Cancer

Third-Generation ALK Inhibitors for NSCLC

Prognostic Subgroups in Advanced Bladder Cancer

<< Prev Page

Next Page >>

Featured

The Evolving Landscape of Immunotherapy for NSCLC

A video editorial series that features expert opinions on multiple areas of focus.

View more >>>

Featured

FDA Approves Blinatumomab for MRD+ ALL

The FDA has granted an accelerated approval to blinatumomab for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia who are in remission but still have minimal residual disease.

View more >>>

Featured Video

Immunotherapy in the Treatment of Follicular Lymphoma

Ian W. Flinn, MD, PhD; Grzegorz S. Nowakowski, MD; Loretta J. Nastoupil, MD; and Anas Younes, MD, reflect on the value of immunotherapy, immunotherapy combination strategies, and understanding the tumor microenvironment in treating follicular lymphoma.View now

FDA Approvals in RCC and Chronic ITP, 2018 ELCC Highlights, and More